Medical World News® Deep Dive: Making Cell and Gene Therapy Practical

Video

Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.

In a recent episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Josh Ludwig, the global director of commercial operations at ScaleReady, about how a joint venture launched in January 2021 between Bio-Techne, Fresenius Kabi, and Wilson Wolf is uniquely positioned to make cell and gene therapy practical and viable for patients with cancer.

Ludwig discussed how ScaleReady can support the entire industry, now and into the future, with a manufacturing platform that delivers a high throughput and efficient use of space. He also detailed G-Rex closed-system bioreactors, important processes for successful commercialization of cell and gene therapy, and future efforts utilizing ScaleReady.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.
Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.
Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Related Content
Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care

Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care

Carl He, MD
September 24th 2024
Article

Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications

FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications

Ariana Pelosci
September 12th 2024
Article

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Neil M. Iyengar, MD
August 21st 2024
Article

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

Further development of vebreltinib in patients with MET fusions is being considered following results from the phase 2 SPARTA trial.

Vebreltinib Achieves Preliminary Responses in Non-CNS MET+ Solid Tumors

Roman Fabbricatore
August 21st 2024
Article

Further development of vebreltinib in patients with MET fusions is being considered following results from the phase 2 SPARTA trial.